Sophie Moog

Sophie Moog

Auto-generated profile, based on publicly available information

Sophie Moog

Département d’Imagerie, Service d’Oncologie Endocrinienne, Gustave Roussy, 114 Rue Edouard Vaillant, 94805 Villejuif, France

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2021 in Cancer Research
Verified
Journal Article
Open access
PDF file
JGJudith Goncalves
Judith Goncalves
SMSophie Moog
Sophie Moog
AMAurélie Morin
Aurélie Morin
GGGeraldine Gentric
Geraldine Gentric
SMSebastian Müller
Sebastian Müller
JFJudith Favier
Judith Favier
Succinate dehydrogenase is a key enzyme in the tricarboxylic acid cycle and the electron transport chain. All four subunits of succinate dehydrogenase are tumor suppressor genes predisposing to paraganglioma, but only mutations in the SDHB subunit are associated with increased risk of metastasis. Here we generated an Sdhd knockout chromaffin cell line and compared it with Sdhb-deficient cells. Both cell types exhibited similar SDH loss of function, metabolic adaptation, and succinate accumulation. In contrast, Sdhb−/− cells showed hallmarks of mesenchymal transition associated with increased DNA hypermethylation and a stronger pseudo-hypoxic phenotype compared with Sdhd−/− cells. Loss of SDHB specifically led to increased oxidative stress associated with dysregulated iron and copper homeostasis in the absence of NRF2 activation. High-dose ascorbate exacerbated the increase in mitochondrial reactive oxygen species, leading to cell death in Sdhb−/− cells. These data establish a mechanism linking oxidative stress to iron homeostasis that specifically occurs in Sdhb-deficient cells and may promote metastasis. They also highlight high-dose ascorbate as a promising therapeutic strategy for SDHB-related cancers. Significance: Loss of different succinate dehydrogenase subunits can lead to different cell and tumor phenotypes, linking stronger 2-OG–dependent dioxygenases inhibition, iron overload, and ROS accumulation following SDHB mutation.

4 August 2022 in Cancers
Verified
Journal Article
Open access
PDF file
CSClotilde Sparano
Clotilde Sparano
SMSophie Moog
Sophie Moog
JHJulien Hadoux
Julien Hadoux
CDCorinne Dupuy
Corinne Dupuy
AGAbir Al Ghuzlan
Abir Al Ghuzlan
LLLivia Lamartina
Livia Lamartina
Radioiodine treatment (RAI) represents the most widespread and effective therapy for differentiated thyroid cancer (DTC). RAI goals encompass ablative (destruction of thyroid remnants, to enhance thyroglobulin predictive value), adjuvant (destruction of microscopic disease to reduce recurrences), and therapeutic (in case of macroscopic iodine avid lesions) purposes, but its use has evolved over time. Randomized trial results have enabled the refinement of RAI indications, moving from a standardized practice to a tailored approach. In most cases, low-risk patients may safely avoid RAI, but where necessary, a simplified protocol, based on lower iodine activities and human recombinant TSH preparation, proved to be just as effective, reducing overtreatment or useless impairment of quality of life. In pediatric DTC, RAI treatments may allow tumor healing even at the advanced stages. Finally, new challenges have arisen with the advancement in redifferentiation protocols, through which RAI still represents a leading therapy, even in former iodine refractory cases. RAI therapy is usually well-tolerated at low activities rates, but some concerns exist concerning higher cumulative doses and long-term outcomes. Despite these achievements, several issues still need to be addressed in terms of RAI indications and protocols, heading toward the RAI strategy of the future.

1 November 2024 in Radiology
Verified
Journal Article
Closed access
LDLama Dawi
Lama Dawi
YBYounes Belkouchi
Younes Belkouchi
LLLittisha LAWRANCE
Littisha LAWRANCE
OGOthilie Gautier
Othilie Gautier
SASAMY AMMARI
SAMY AMMARI
NLNathalie Lassau
Nathalie Lassau
Tumor fraction at liquid biopsy was weakly correlated with the total tumor volume at contrast-enhanced CT and did not accurately reflect the tumor burden at contrast-enhanced CT.

29 December 2023 in Cancers
Verified
Journal Article
Open access
PDF file
JGJoanne Guerlain
Joanne Guerlain
IBIngrid Breuskin
Ingrid Breuskin
Muriel AbbaciMuriel Abbaci
Muriel Abbaci
LLLivia Lamartina
Livia Lamartina
JHJulien Hadoux
Julien Hadoux
DHDana M. Hartl
Dana M. Hartl
Hypoparathyroidism is the most frequent complication in thyroid surgery. The aim of this study was to evaluate the impact of intraoperative parathyroid gland identification, using autofluorescence imaging, on the rate of post-operative (PO) hypoparathyroidism in thyroid cancer surgery. Patients undergoing total thyroidectomy with central neck dissection from 2018 to 2022 were included. A prospective cohort of 77 patients operated on using near-infrared autofluorescence (NIRAF+) with the Fluobeam® (Fluoptics, Grenoble, France) system was compared to a retrospective cohort of 94 patients (NIR−). The main outcomes were the rate of PO hypocalcemia, with three cutoffs: corrected calcium (Cac) < 2.10 mmol/L, <2.00 mmol/L and <1.875 mmol/L, and the rate of permanent hypoparathyroidism, at 12 months. The rate of PO Cac < 2.10 mmol/L was statistically lower in the NIRAF+ group, compared to the control group (36% and 60%, p = 0.003, respectively). No statistically significant difference was observed for the other two thresholds. There was a lower rate of permanent hypoparathyroidism in the NIRAF+ group (5% vs. 14% in the control group), although not statistically significant (p = 0.07). NIRAF is a surgically non-invasive adjunct, and can improve patients’ outcomes for thyroid cancer surgery by reducing post-operative temporary hypoparathyroidism. Larger prospective studies are warranted to validate our findings.

1 January 2022 in Cancer Letters
Verified
Journal Article
Closed access
LSLaura Streit
Laura Streit
SMSophie Moog
Sophie Moog
SHSylvain Hugel
Sylvain Hugel
MRMarion Rame
Marion Rame
ETEmeline Tanguy
Emeline Tanguy
SGStéphane Gasman
Stéphane Gasman

1 June 2022 in Endocrine-Related Cancer
Verified
Journal Article
Closed access
PDF file
SMSophie Moog
Sophie Moog
BSBetty SALGUES
Betty SALGUES
YBYasmine Braik-Djellas
Yasmine Braik-Djellas
TVThomas Viel
Thomas Viel
DBDaniel Balvay
Daniel Balvay
JFJudith Favier
Judith Favier
Therapies for metastatic SDHB-dependent pheochromocytoma and paraganglioma (PPGL) are limited and poorly efficient. New targeted therapies and identification of early non-invasive biomarkers of response are thus urgently needed for these patients. We characterized an in vivo allograft model of spontaneously immortalized murine chromaffin cells (imCC) with inactivation of the Sdhb gene by dynamic contrast-enhanced MRI (DCE-MRI) and 18FDG-PET. We evaluated the response to several therapies: IACS-010759 (mitochondrial respiratory chain complex I inhibitor), sunitinib (tyrosine kinase inhibitor with anti-angiogenic activity), talazoparib (poly ADP ribose polymerase (PARP) inhibitor) combined or not to temozolomide (alkylating agent), pharmacological inhibitors of HIF2a (PT2385 and PT2977 (belzutifan)) and molecular inactivation of HIF2a (imCC Sdhb−/− shHIF2a). Multimodal imaging was performed, including magnetic resonance spectroscopy (1H-MRS) to monitor the level of succinate in vivo. The allografted model of Sdhb−/− imCC reflected SDHB-deficient tumors, with increased angiogenesis and a particular avidity for 18FDG. After 14 days of treatment, IACS-010759, sunitinib and talazoparib at high doses allowed a significant reduction of the tumor volumes. In contrast to the tumor growth inhibition observed in Sdhb−/− shHIF2a imCC tumors, pharmacological inhibitors of HIF2a (PT2385 and belzutifan) showed no antitumor action in this model, alone or in combination with sunitinib. 1H-MRS, but not DCE-MRI, enabled the monitoring response to sunitinib, which was the best treatment in this study, promoting a decrease in succinate levels detected in vivo. This study paves the way for new therapeutic options and reveals a potential new early biomarker of response to treatment in SDHB-dependent PPGL.